Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals ($ALNY) announced an update on their ongoing clinical study. The Phase 2 study “A Phase 2, Randomized, Double-blind, Placeb...

Alnylam’s New Hypertension Combo Study Could Reshape Its Long-Term Value

Alnylam Pharmaceuticals ($ALNY) announced an update on their ongoing clinical study. Alnylam Pharmaceuticals is running a Phase 1/2 trial called “A...

Alnylam Steps Into Obesity Drug Race With New ALN-2232 Trial

Alnylam Pharmaceuticals ($ALNY) announced an update on their ongoing clinical study. The Phase 1 study “A Study to Evaluate ALN-4915 in Adult Healt...

Alnylam’s New Phase 1 ALN-4915 Trial: Early Safety Data in Focus for ALNY Investors

Alnylam Pharmaceuticals ($ALNY) announced an update on their ongoing clinical study. Alnylam Pharmaceuticals is preparing a Phase 2 trial called “H...

Alnylam’s HMBeacon Trial Adds a New Growth Angle in Women’s Bleeding Disorders

Using the TipRanks Highest P/E Ratio Stocks tool, we identified three companies with high price-to-earnings (P/E) ratios and more than 40% upside p...

PLTR, KTOS, ALNY: 3 High P/E Stocks with 40%+ Upside Potential in 2026

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arcutis Biotherapeutics (ARQT), The Ensign Group (EN...

Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), The Ensign Group (ENSG) and Alnylam Pharma (ALNY)

In a report released today, William Pickering from Bernstein reiterated a Buy rating on Alnylam Pharma, with a price target of $447.00. According t...

Alnylam Pharma (ALNY) Gets a Buy from Bernstein

Raymond James analyst Tiago Fauth maintained a Hold rating on Alnylam Pharma today and set a price target of $377.00. Fauth covers the Healthcare s...

Raymond James Reaffirms Their Hold Rating on Alnylam Pharma (ALNY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN), Alnylam Pharma (ALNY) and The Ensign...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Alnylam Pharma (ALNY) and The Ensign Group (ENSG)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pacira Pharmaceuticals (PCRX), Cadrenal Therapeutics...

Analysts’ Top Healthcare Picks: Pacira Pharmaceuticals (PCRX), Cadrenal Therapeutics, Inc. (CVKD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Veeva Systems (VEEV), Summit Therapeutics (SMMT) a...

Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Summit Therapeutics (SMMT) and Alnylam Pharma (ALNY)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cerus (CERS) and Alnylam Pharma (ALNY) with bullish ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alnylam Pharma (ALNY) and Alignment Healthcare (ALHC...

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Alignment Healthcare (ALHC)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Axsome Therapeutics (AXSM), Evommune, Inc. (EVMN) an...

Market Cap	$59.82B	P/E Ratio	40.15
52W High	$495.55	52W Low	$284.28
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	31.2%	52W Position	5.3%
Overall Score	35	Value Score	20
Quality Score	65	Technical Score	20

EPS Current Est	$7.36	EPS Next Est	$10.27
EPS Growth Est	+39.5%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ALNY	$295.50	-0.66%	649.71K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ALNY	$295.50	-0.7%	649.71K
3
4
5
6

ALNY

ALNY

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Alnylam Pharmaceuticals Inc. Data in Excel

Get Alnylam Pharmaceuticals Inc. Data in Excel